The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical activity and safety of ASN001, a selective CYP17 lyase inhibitor, administered without prednisone in men with metastatic castration-resistant prostate cancer (mCRPC): A phase 1/2 clinical trial.
 
Jorge A. Garcia
Consulting or Advisory Role - Bayer; Eisai; Exelixis; Genentech/Roche; Medivation; Pfizer; Sanofi
Speakers' Bureau - Bayer; Genentech/Roche; Medivation/Astellas; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Lilly (Inst); Orion (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bayer; Eisai; Exelixis; Genentech/Roche; Medivation/Astellas; Pfizer; Sanofi
 
Robert Dreicer
Honoraria - Astellas Pharma
Consulting or Advisory Role - Asana Biosciences; Astellas Pharma; Exelixis; Ferring; Janssen Oncology; Medivation; Roche
Research Funding - Asana Biosciences (Inst); Genentech (Inst)
 
Allan J. Pantuck
No Relationships to Disclose
 
Naomi B. Haas
Consulting or Advisory Role - Cerulean Pharma; Exelixis; Novartis; Pfizer
Expert Testimony - Lilly (I)
 
Ulka N. Vaishampayan
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Exelixis; Genentech; Janssen; Novartis; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Novartis; Pfizer
Speakers' Bureau - Astellas Pharma; Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Novartis; Pfizer; Sanofi
Research Funding - Astellas Pharma; Bristol-Myers Squibb; Exelixis; Novartis; Pfizer
 
Niranjan Sathyanarayana Rao
Employment - Asana Biosciences
Leadership - Asana Biosciences
Stock and Other Ownership Interests - Asana Biosciences
 
Louis J. Denis
Employment - Asana Biosciences
Leadership - Asana Biosciences
Stock and Other Ownership Interests - Asana Biosciences
 
Anthony W. Tolcher
Employment - START
Leadership - Symphony Evolution
Consulting or Advisory Role - Akebia Therapeutics (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Bayer Schering Pharma (Inst); Bicycle Therapeutics (Inst); Blend Therapeutics (Inst); Boehringer Ingelheim (Inst); Celator (Inst); Elekta (Inst); Endocyte (Inst); Genmab (Inst); Heron (Inst); Ignyta (Inst); Janssen (Inst); Johnson & Johnson (Inst); MEDIAN Technologies (Inst); Merus (Inst); Nanobiotix (Inst); New B Innovation (Inst); OncoMed (Inst); Pierre Fabre (Inst); Rigontec (Inst); Symphony Evolution (Inst); Upsher-Smith (Inst); Zymeworks (Inst)
Research Funding - AbbVie (Inst); ArQule (Inst); Asana Biosciences (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); Cerulean Pharma (Inst); Dicerna (Inst); Endocyte (Inst); Gilead Sciences (Inst); Infinity Pharmaceuticals (Inst); Macrogenics (Inst); Otsuka (Inst); Pfizer (Inst); Plexxikon (Inst); TaiRx, Inc. (Inst)